Table 1.
Patient characteristics (N = 32)
| Median age, years (range) | 63 (44-78) |
|---|---|
| Sex, n (%) | |
| Male | 23 (71.9) |
| Female | 9 (28.1) |
| ECOG PS, n (%) | |
| 0 | 23 (71.9) |
| 1 | 9 (28.1) |
| Primary site, n (%) | |
| Gall-bladder | 7 (21.9) |
| Extrahepatic bile duct | 5 (15.6) |
| Intrahepatic bile duct | 15 (46.9) |
| Ampulla of Vater | 5 (15.6) |
| Extent of disease, n (%) | |
| Unresectable | 25 (78.1) |
| Recurrent | 7 (21.9) |
| Primary chemotherapy (first line), n (%) | |
| GEM + CDDP | 23 (71.9) |
| GEM + CDDP + S-1 | 9 (28.1) |
| Microsatellite instability status, n (%) | |
| Stable | 27 (84.4) |
| High | 0 (0.0) |
| Unknown | 5 (15.6) |
| Biliary drainage, n (%) | |
| Presence | 14 (43.8) |
| Absence | 18 (56.3) |
| Use of antibiotics, n (%)a | |
| Yes | 9 (28.1) |
| No | 23 (71.9) |
CDDP, cisplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; GEM, gemcitabine.
a
Within 1 month before the start of treatment.